Tag: late stage chronic kidney disease drugs market growth

  • Understanding the Late Stage Chronic Kidney Disease Drugs Market’s Growth Prospects from 2024 to 2033

    Understanding the Late Stage Chronic Kidney Disease Drugs Market’s Growth Prospects from 2024 to 2033

    Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

    2024-2033 Forecast: What is the Projected Growth Rate for the Late Stage Chronic Kidney Disease Drugs Market?

    The market size of drugs for late-stage chronic kidney disease has seen significant expansion in previous years. It is anticipated to increase from $6.38 billion in 2023 to $7.16 billion in 2024, demonstrating a compound annual growth rate (CAGR) of 12.2%. The historic development was fueled by advancements in diagnostic methods, an ageing populace, a rise in diabetes and hypertension cases, heightened knowledge of kidney diseases, and the growth of pharmaceutical research and development.

    Anticipations point towards a swift expansion in the market size of drugs for late-stage chronic kidney disease in the ensuing years. The market is predicted to escalate to $10.94 billion by 2028, advancing at a compound annual growth rate (CAGR) of 11.2%. This anticipated growth within the specified period may be credited to factors such as increased spending on healthcare, the adoption of precision medicine methodology, a rising focus on regenerative medicine, an intensified emphasis on patient-oriented care, and worldwide initiatives to raise awareness about kidney diseases. The forecast period is set to witness certain trend changes including the expansion of regenerative medicine therapies, the ascent in telemedicine services for handling chronic kidney disease, the evolution of combination therapies, focus on strategies for early intervention, and the growing attraction towards diagnostics based on biomarkers.

    Claim Your Free Sample of the Global Late Stage Chronic Kidney Disease Drugs Market Report Today!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=12196&type=smp

    What Are the Main Drivers Behind the Growth of the late stage chronic kidney disease drugs Market?

    The increasing incidence of long-term kidney diseases is predicted to stimulate the expansion of the late-stage chronic kidney disease drug market. These diseases encompass a variety of conditions that impact the kidneys’ structure and function. Drugs for late-stage chronic kidney disease aim to regulate blood pressure in patients, reduce protein loss to prevent further kidney degradation, handle symptoms, and sidestep complications. For instance, the Centers for Disease Control and Prevention, a Department of Health and Human Services in the US, reported in July 2022 that approximately 15%, or 37 million people in the US, were suffering from kidney ailments. The occurrence rate is 12% among people aged 45-64, while those aged 18 to 44 show the lowest prevalence at 6% in 2021. As such, the high frequency of chronic kidney disease is propelling the growth of the late-stage chronic kidney disease drug market.

    What Are the Primary Segments of the Late Stage Chronic Kidney Disease Drugs Market?

    1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders

    2) By Indication Type: Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalemia

    3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

    Which Trends Are Revolutionizing the Late Stage Chronic Kidney Disease Drugs Market?

    The trend of product innovation is picking up steam in the late-stage chronic kidney disease drug market. Major market players are creating new drug products to maintain their dominance. For example, in February 2022, Bayer, a pharmaceutical and biotechnology firm from Germany, introduced Kerendia (finerenone) in India. This first-in-class non-steroidal, selective mineralocorticoid receptor antagonist should be used by patients suffering from type two diabetes and chronic renal disease. It operates by inhibiting the over-stimulation of the mineralocorticoid receptor (MR), which is believed to contribute to the onset of chronic kidney disease (CKD) and cardiovascular damage.

    Order Now for Fast Delivery of Your Late Stage Chronic Kidney Disease Drugs Market Report!

    https://www.thebusinessresearchcompany.com/report/late-stage-chronic-kidney-disease-drugs-global-market-report

    Which Geographical Regions Are Pioneering Growth in the Late Stage Chronic Kidney Disease Drugs Market?

    North America was the largest region in the late stage chronic kidney disease drugs market in 2023. The regions covered in the late stage chronic kidney disease drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    The Late Stage Chronic Kidney Disease Drugs Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the late stage chronic kidney disease drugs market, its market share, and analyzes key competitors along with their market positions.

    The Table Of Content For The Late Stage Chronic Kidney Disease Drugs Market Include

    1. Late Stage Chronic Kidney Disease Drugs Market Executive Summary

    2. Late Stage Chronic Kidney Disease Drugs Market Segments

    3. Late Stage Chronic Kidney Disease Drugs Market Size And Template Market Growth Rate

    4. Key Late Stage Chronic Kidney Disease Drugs Market Trends

    5. Major Late Stage Chronic Kidney Disease Drugs Market Drivers

    ……

    25. Key Mergers And Acquisitions In The Late Stage Chronic Kidney Disease Drugs Market

    26. Top Late Stage Chronic Kidney Disease Drugs Companies

    27. Late Stage Chronic Kidney Disease Drugs Market Opportunities And Strategies

    28. Late Stage Chronic Kidney Disease Drugs Market, Conclusions And Recommendations

    29. Appendix

    Learn More About The Business Research Company

    The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • What’s The Growth Forecast For Late Stage Chronic Kidney Disease Drugs Market Through 2024-2033?

    What’s The Growth Forecast For Late Stage Chronic Kidney Disease Drugs Market Through 2024-2033?

    The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

    Introduction:

    The late-stage chronic kidney disease (CKD) drugs market has witnessed rapid expansion, driven by factors such as advancements in diagnostic capabilities, an aging population, and increased prevalence of predisposing conditions like diabetes and hypertension. This growth trajectory is expected to persist, fueled by rising healthcare expenditure and a shift towards precision medicine approaches.

    Surging Prevalence of Chronic Kidney Diseases Sparks Growth:

    • The prevalence of chronic kidney diseases is on the rise globally, necessitating effective treatment options.
    • Late-stage CKD drugs play a crucial role in managing symptoms, controlling blood pressure, and slowing disease progression.
    • Statistics from the Centers for Disease Control and Prevention highlight the substantial burden of kidney disease, particularly among specific age groups in the US.

    Product Innovation in Late-Stage Chronic Kidney Disease Drug Market:

    • Innovation drives competitiveness in the late-stage CKD drugs market, leading to the development of novel treatment options.
    • Bayer’s launch of Kerendia (finerenone) in India exemplifies advancements in non-steroidal, selective mineralocorticoid receptor antagonists for type two diabetes and chronic renal disease.

    View More On The Late Stage Chronic Kidney Disease Drugs Market Report 2024 – https://www.thebusinessresearchcompany.com/report/late-stage-chronic-kidney-disease-drugs-global-market-report

    AstraZeneca Expands Cardiorenal Pipeline with CinCor Pharma Inc. Acquisition:

    • Strategic acquisitions bolster companies’ capabilities in addressing complex disease conditions.
    • AstraZeneca’s acquisition of CinCor Pharma Inc. enhances its cardiorenal pipeline with baxdrostat (CIN-107), an aldosterone synthase inhibitor for chronic kidney disorders.

    Segmentation of the Late-Stage Chronic Kidney Disease Drugs Market: The market is segmented based on:

    1. Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders.
    2. Indication Type: Late-Stage CKD Induced Hyperparathyroidism, Hyperphosphatemia, Hyperkalemia.
    3. Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies.

    Regional Insights:

    • North America emerged as the largest region in the late-stage chronic kidney disease drugs market in 2023, driven by advanced healthcare infrastructure.
    • The region’s leadership underscores the importance of effective treatment strategies for managing CKD complications.

    Future Outlook and Trends:

    • The late-stage CKD drugs market is forecasted to reach $10.94 billion by 2028, driven by global initiatives for kidney disease awareness and precision medicine adoption.
    • Major trends include expansion of regenerative medicine therapies, integration of telemedicine services, and emphasis on early intervention strategies.

    Conclusion: The late-stage chronic kidney disease drugs market is witnessing robust growth, propelled by innovation, strategic acquisitions, and a growing understanding of disease mechanisms. With a focus on precision medicine and patient-centered care, stakeholders aim to address the evolving needs of individuals affected by late-stage CKD, offering hope for improved outcomes and quality of life.

    Request A Sample Of The Global Late Stage Chronic Kidney Disease Drugs Market Report 2024:
    https://www.thebusinessresearchcompany.com/sample_request?id=12196&type=smp